BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 1,531 Shares of United Therapeutics Co. (NASDAQ:UTHR)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 17.9% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 7,034 shares of the biotechnology company's stock after selling 1,531 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in United Therapeutics were worth $2,521,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. LSV Asset Management boosted its stake in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock worth $307,837,000 after acquiring an additional 436,851 shares during the period. FMR LLC boosted its position in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after purchasing an additional 314,004 shares during the period. Assetmark Inc. boosted its position in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock worth $150,492,000 after purchasing an additional 152,249 shares during the period. Pacer Advisors Inc. increased its holdings in shares of United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of United Therapeutics by 49.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company's stock valued at $88,089,000 after purchasing an additional 91,597 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 15,000 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $401.44, for a total value of $6,021,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 7,796 shares of the company's stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84. Following the transaction, the chief financial officer now owns 4,264 shares of the company's stock, valued at $1,509,626.56. This trade represents a 64.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 119,442 shares of company stock valued at $44,577,770 over the last ninety days. 11.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research analyst reports. TD Cowen lifted their target price on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Wells Fargo & Company increased their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 20th. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Down 0.0 %

Shares of NASDAQ:UTHR traded down $0.03 during midday trading on Thursday, hitting $374.37. The stock had a trading volume of 241,661 shares, compared to its average volume of 452,964. The company has a market capitalization of $16.72 billion, a P/E ratio of 16.44, a price-to-earnings-growth ratio of 1.07 and a beta of 0.54. The company's 50-day moving average price is $368.58 and its 200-day moving average price is $337.70. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period in the prior year, the company earned $5.38 earnings per share. The company's quarterly revenue was up 22.9% on a year-over-year basis. Research analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.